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INTRODUCTION 
 
1.1. SUSTAINED RELEASE DOSAGE FORMS2,8,9 
 Probably the earliest work in the area of sustained drug delivery forms can 
be traced to the 1938 patent of Israel Lipowski. There has been 60 years of 
research and development experience in the sustained drug release area since the 
patent, and a number of strategies have been developed to prolong drug level in the 
body. These ranges form the very simple slowly dissolving pellets or tablets to the 
more technologically sophisticated “controlled drug release systems” which have 
recently started to appear on the market and in the pharmaceutical literatures. 
 
 With many drugs, the basic goal of therapy is to achieve a steady-stage 
blood or tissue level that is therapeutically effective and nontoxic for an extended 
period of time. The design of proper dosage regimens in an important element in 
accomplishing this goal. In the recent past, controlled release concept and 
technology have received increasing attention in the face of growing awareness to 
toxicity and ineffectiveness of drugs when administered or applied by conventional 
methods. Thus drug  administered in the form of tablets, capsules, injectables and 
ointements etc., usually produce wide ranging fluctuations in drug concentration in 
the blood stream and tissues with consequent undesirable toxicity and poor 
efficiency. This factor as well as factors such as repetitive dosing and 
unpredictable absorption led to the concept of controlled drug delivery systems or 
therapeutic systems. A dosage form that one or more drugs continuously in a pred 
pattern for a fixed period of time, either systemically or to a specified target 
organm is a controlled drug delivery system. The advent of drug delivery systems 
brings rate controlled delivery with fewer side effects, increased efficacy and 
constant delivery. The primary objectives controlled drug delivery is to ensure 
safety of drugs as well as patient compliance.  
 
 Controlled release drug administration means not only prolonged duration of 
drug delivery, as in sustained released and prolonged released, but also implies 
predictability and reproducibility of drug release kinetics. 
 
 Description such as retard, slow, gradual, controlled, continuous, sustained, 
programmed, fractionated, deferred and pulsatile – release dosage forms and other 
similar definitions should be redefined as one of the following definitions. 
  
 Prolonged release dosage forms, that there may not be control of release 
rate, but prolong therapeutic blood or tissue level of the drug for an extend  period 
of time. .  
 
 Delayed or repeated dosage forms that release the dose or a part (or parts) of 
the dose at a time (or times) different from  that immediately following 
administration. 
 
 Oral sustained action products are of two kinds depending on the way in 
which the maintaining dose is released. For the so called repeat action and timed 
release products the maintaining does become available at discrete time intervals. 
If the maintain drug is continuously released, the product is of the prolonged action 
of sustained release type. 
 
 The goal of any drug delivery systems is to provide a therapeutic amount of 
drug to the proper site in the body to achieve promptly and then maintain the 
desired drug concentration. Two aspects are most important to drug delivery, 
namely, spatial pl acement and temporal delivery of a drug. Spatial placement 
related to targeting a drug to a specific organ or tissue. While temporal delivery 
refers to controlling the rate of drug delivery to the target tissue. An appropriately 
designed sustained-release drug delivery system can be a major advance towards 
solving these two problems.  
 
 The goal in designing sustained or controlled delivery systems is to reduce 
the frequency of dosing or to increase effectiveness of the drug delivery. If one 
were to imagine the ideal drug delivery system, two perquisites would be required. 
First, it would be a single dose for the duration of treatment. Whether it be for days 
or weeks, as with infection, or for the lifetime of the patient, as in hypertension or 
diabetes. Second, it should delivery the active entity  directly to the site of action, 
there by minimizing or eliminating side effects. 
 
 
 
 
 
 
 
 
 
 
1.2 TERMINOLOGY1,3,10 
 There is considerable confusion in the terminology. The conventional 
dosage forms are immediate release types. Non-immediate delivery systems may 
be divided into three categories. 
 
1. Delayed release 
2. Sustained release 
a. Controlled release 
b. Prolonged release 
3. Site-specific and receptor release 
 
1. Delayed release 
 Delayed release systems are those that utilize repetitive, intermittent dosing 
of drug form one or more immediate release units incorporated into a single dosage 
form. Examples of delayed release systems include repeat action tablets and 
capsules. A delayed release dosage form doses not product or maintaining drug 
blood levels with in the therapeutic range as shown in fig. 1 
 
2. Sustained Release System  
 It includes any drug delivery system that achieves slow release of drug over 
an extended period of time. 
 
a. Controlled release system 
If the system is successful at maintaining constant drug levels in  the 
blood or target tissue, it is considerable a Controlled release system. 
 
b. Prolonged release system 
If the system is unsuccessful at maintaining constant levels, the  
           duration of action is extended over that achieved by conventional  
            delivery, it is considered a prolonged release system. This  
 
 
Fig.1. 
Hypothetical plasma concentration – time profile from conventional multiple 
dosing and single doses of sustained and controlled delivery formulations.  
 
3. Site Specific And Receptor Release 
 It refers to targeting of a drug directly to a certain biological location. In the 
case of site specific release, the target is a certain organ or tissue, while for 
Receptor Release the particular Receptor for a drug within an organ or tissue. Both 
of these systems satisfy the spatial aspect of drug delivery. 
1.3. Requirements for sustained drug release11,15,30 
 Design of sustained release products is normally a very difficult task because 
of the interplay of the physical-chemical-biological properties of the drug, the 
patient disease state, and technological limitation in fabrication of the final dosage 
form. Depending on the drug, disease state, route of administration, but a before a 
final decision is made to proceed with the dosage form, all the these factors must 
be considered. 
 
(A) Release rate and dose calculation  
 The objective in designing a SR system is to deliver a drug at a rate 
necessary to achieve and maintain a constant drug blood level. The rate of delivery 
must be independent of the amount of the drug remaining in the dosage in the 
dosage form and constant over time. That is, release from the dosage form should 
follow zero- order kinetics as shown zero-order kinetics as shown by the following 
equation. 
Kr = Rate In= Rate out = Ke. Cd.Vd   
Where 
Kr = Zero-order rate constant for drug release (among / time) 
Ke = First – order rate constant for overall drug elimination (time-1) 
Cd = desired drug level in the body (amount / Volume) 
Vd = volume space in which the drug is distributed. 
 
 To achieve a therapeutic level promptly and sustain the level for a given 
period of time, the dose form generally consist of two parts. 
 
 W  =  Di + Dm 
 Where,  
 W  =  the total dose 
 Di  =  an initial priming dose 
 Dm  =  maintaining or sustaining dose.  
(B) Drug properties 
 There are a number of physico-chemical and derived biological properties of 
the drug that either preclude placement of the drug in  a sustained release system, 
or have an adverse influence on product design, making formulation of a SR 
system difficult, but not impossible. Thus b y changing the type of sustaining 
mechanism, the dose, or the route of administration; it might be possible to design 
a SR system.  
 
1.4 Factors  influencing the design of a SR dosage form 6,28,29 
1.4.1Physico-chemical properties 
1.Dose 
 Drugs with a single oral dose larger than 0.5 gram are poor candidates for 
oral controlled products. A larger dose will generate a substantial volume 
depending on the density of the drug, duration of intended prolongation and 
mechanism of absorpti on. But the problem of large dose can be overcome by 
selecting an alternate route of drug administration. 
 
 
 
 
 
2. Aqueous solubility 
The aqueous solubility of a drug is an extremely important consideration in 
its incorporation into controlled release form. Extremes in aqueous solubility are 
undesirable in the preparation of controlled release products. Aqueous solubility 
exercises its control on the absorption process in two ways (a) by its influence on 
the dissolution rate and (b) by its ability to penetrate the tissues. Dissolution rate 
has limited the absorption of a variety of drugs. For e.g. griseofulvin, digoxin, 
salicylamide, diazoxide and warfarin. A drug with aqueous solubility less than 
0.01mg/ml is a poor candidate as a controlled release product since the drug is 
inherently sustained. For drug with low water solubility, it will be difficult to 
incorporate into a SR formulation.  
 
The lower limit on solubility of such product has been reported to be 0.1 
mg/ml hydrolysis or metabolism in the stomach and intestine is proportional to the 
residence time in these organs and the apparent rate constant for degradation. If the 
drug is in a solid form, only a small fraction of it will be in solution for possible 
degradation. Hence, it would appear possible to improve the apparent 
bioavailability of a drug which is unstable in the stomach by placing it in a slowly 
soluble or slowly available form. Since most controlled drug systems are designed 
to release their contents over much of the length of the gastro intestional tract, 
drugs which are unstable in the environment of intestine would be unusable to be 
formulated into such delivery systems. In addition to chemical degradation, 
metabolizing enzymes at the site of administration or along the pathway to the 
target area may also playa a significant role in drug availability. 
 
5.Molecular size 
 Large molecules will show small diffusion coefficients and may be difficult 
to place into a suitable sustained release system. Drug of molecular weight up to 
500-700 should present no difficulty in this regard. 
 
 The ability of a drug to diffuse through membrane, its so called diffusivity 
can be influenced by its molecular size as shown in equation. 
 
 Log D = - SV long V+ KV= -SM log M+KM 
 Where  D is the diffusivity, M is molecular weight, V is molecular volume 
and SV, SM, KV, KM are constants. Molecular size of a drug is an important 
parameter that must be considered if a polymeric membrane is relied upon for the  
controlled release mechanism . The diffusion coefficient also plays a role in the 
ability of a drug to cross a biological membrane.    
 
1.4.2 Biological Properties 
1.Absorption  
 The rate, extent and uniformity of absorption of a drug are important factors 
when considering its formulation into sustained release system. Since the rate-
limiting step in drug delivery from a sustained release system is release form the 
dosage forms rather than absorption, a rapid rate of absorption of the drug relative 
to its release is essential if the system is to be successful. 
 
  Kr <<<<  Ka  
 This becomes most critical in the case of oral administration  
 Drug that are slowly absorbed or absorbed with a variable absorption rate 
are poor candidates for a SR system. For a oral dosage forms, the lower limit on 
the absorption rate constant is in the range of 0.25h-1 (assuming a GI transit time of 
10-12hr). 
 To maintain a constant blood or tissue level of drug it must be uniformly 
release from the controlled release products and then uniformly absorbed. The 
fraction of drug absorbed from a conventional dosage form can sometimes be quite 
low for a variety of reasons, such as3. drug degradation due to metabolism, binding 
of drug to proteins and physical loss. Placement of labial drug in controlled drug 
delivery systems can sometimes improved the fraction of dose absorbed.  
 
 Drugs absorbed by specialized transport processes and drugs absorbed at 
special sites of the gastro intestinal tract are also poor candidates for real controlled 
release products. Drugs which are slowly absorbed are also not good for controlled 
release dosage forms primarily because drug availability is limited by gastro 
intestinal transit time.  
 
2.Distribution  
 The design of sustained release systems usually based on only a few 
pharmacokinetic parameters one of which is the volume of distribution, expressed 
by following equation. 
   V = dose/C0 
Where,  
 Co= drug concentration immediately after an I.V. bolus injection but before 
any drug has been eliminated. 
 The distribution of a drug into vascular and extra-vascular spaces in the 
body is an important. factor in its overall elimination kinetics. His in turn sustained 
release system, primarily by restricting the magnitude of release rate and the dose 
size, which can be employed. 
 Drugs with high apparent volumes of distribution, which in turn influences 
the rate of elimination for the drug, are poor candidates. 
 
3.Metabolism 
 The metabolic  conversion of a drug to another  chemical form can usually 
be considered in the design of sustained release systems for that drug. As long as 
the location rate and extent of metabolism are known and the rate constants for 
process are not too large, successful sustained release product can be developed. 
 There are two factors associated with the metabolism fo some drugs 
however which present problems for their use in sustained release systems. One is 
the ability of a drug it included or inhibits enzyme synthesis. This may result in 
fluctuation in drug blood level with chronic dosing. The other is fluctuation in drug 
blood level due to intestinal metabolism or through hepatic first pass effect.  
 
 SR systems for drugs, which are extensively metabolized, are possible as 
long as the rate of metabolism is not too great nor the metabolism variable with 
gastro-intestinal transit or other routes. 
 
 
 
 
4.Elimination and biological half-life 
 The rate of elimination of a drug is quantitatively described by its biological 
half life (t ½ ). The half-life of a drug is related to its apparent volume of 
distribution V and its systemic clearance.  
  T ½  = 0.693 V/Cls  = 0.693 V. AUC / Dose 
Where,  
  Cls  = Systemic Clearance 
 And is equal to the ratio of an IV administered dose to the total area under 
the curve versus time curve. It is difficult to define precise upper and lower limits 
for the value of the half-life of a drug that best suits it for sustained release 
formulations. In general however, a drug with a half- life of less than two hours 
should probably not be used. 
 
 Since such systems will require unacceptably large release rates and large 
doses. At the other extremes a drug with a half-life of greater than 8 hours should 
also probably not be used formulation of such a drug SR systems is unnecessary. 
 
5.Duration of action  
 The biological half- life and hence the duration of action of a drug obviously 
plays a major role in considering a drug for SR systems drugs with short half – 
lives and high doses impose a constraint because of the dose size needed and those 
with long half-lives are inherently sustained. 
6.Therapeutic Index 
 Drugs with a narrow therapeutic range require precise control over the blood 
levels of drug, placing a constraint on SR dosage forms. 
 The most widely used measured of the margin of safety of a drug is its 
therapeutic index (TI). 
  TI = TD50 / ED50 
Where,  
 TD50 = Median toxic dose 
 ED50 = Median effective dose. 
1.4.3 Other factors in a controlled release formulation  
 
1.Transit time 
 The transit time up to 2 hours approximately, limits the extent of 
prolongation possible with oral controlled release products.  
 
2.Gastric emptying time 
 Variation in gastric emptying time and intestinal peristaltic activity affects 
the absorption. For example, aspirin microcapsules. 
 3.First pass hepatic effect 
 The drugs, which are suspected of undergoing a first pass hepatic 
metabolism, should not be formulated as an oral preparation. For example acetyl 
Salicylic acid, cortisone, morphine, indomethacin etc.  
 
4.Environmental conditions 
 These vary for drugs along the gastro intestinal tract and certain drugs are 
preferentially absorbed at particular regions; vitamin B2 is absorbed high up in the 
gastro intestinal tract  particularly in the upper duodenal area by an active transport 
mechanism that is saturable so that little is absorbed in the lower intestine.  
5.Biological half – life 
 The biological half- life of the drug is very important. Drugs such as 
ampicillin, cloxacillin, furosemide, levodopa, and prophythiouracil have short half- 
lives and therefore require frequent dosing to maintain an adequate therapeutic 
level. Also, there is little medical rational for the use of a controlled release 
formulation in the case of drugs with a long biological half-life, since the drugs are 
inherently long acting. 
1.5 Potential benefits derived from sustained release systems13,14,27 
 The potential benefits that a sustained release system may bring to use can 
be appreciated by a consideration of prolonged and efficient delivery of 
therapeutically effective dosages, patient compliance and localization of the 
therapy. 
 The bioavailability of drug molecules to the ailing tissue cells is governed by 
a sequence of pharmacokinetics processes release, absorption, absorption, 
distribution, metabolism and elimination. In some cases, these processes result in 
the inefficient bioavailability of the drug to the target tissue cells. The 
bioavailability to a target tissue can be maximized and applying the principles of 
sustained release system can minimize the adverse side effects in non-target tissue. 
 
 Administration of drugs in convetntional dosage forms (except via i.v 
infusion at a constant rate) result in fluctuations of drug concentration in systemic 
circulation. 
 
 A well designed, sustained release system can reduce the frequency of drug 
dosing and also maintain concentration in blood circulation and target tissue cells. 
The pronounced fluctuations resulting from the conventional drug administration 
are likely to yield periods of no therapeutic effect when the drug concentration falls 
below minimum effective dose level (MED) and period of adverse reactions when 
the drug concentration exceeds the dose level. Drug concentrations can be maintain 
within a narrow therapeutic range by the use of sustained release  systems that will 
also minimize the incidence and severity of adverse side effects. 
 
 The controlled or sustained release dosage forms are designed to 
complement the pharmaceutical activity of thye medicament in order to achieve 
better selectivity and longer duration of action. 
 
 
1.5.1 Advantages of Sustained Release formulation 6,7 
1. Improved Therapy 
a. The dosage forms provide uniform drug availability blood levels unlike 
peak and valley pattern obtained by intermittent administration. 
b. The incidence and intensity of undesirable side effects caused by 
excessively high peak drug concentration resulting from the 
administration of conventional dosage forms is reduced. 
c. The missing of the dose cannont occur due to by patients non-
compliance. 
2. Patient convenience 
Frequency of administration is reduced and this disturbance to the 
patient is less particularly at nigh (testing time). 
 
 
3. Economy 
a. Sometimes sustained release formulations are less expensive that 
conventional dosage forms. 
b. Economy may also be affected due to decreased cost of nursing time for 
administration of drugs. 
c. A decrease in the total dose of the drug necessary. 
4. In a sustained release formulation the active ingredient is released at a 
predetermined rate for a predetermined period. 
5. A more efficient utilization of the drugs in the body; example-controlled 
release aspirin provides sufficient drug so that an awakening, the arthritic 
patients has symptomatic relief.  
6. Patient acceptance of the product compared to conventional dosage form. 
 
1.5.2 Disadvantages 
1. Usually the amount of drug in a sustained release dosage form in 3-5 
times and if a dosage form is used improperly e.g. by chewing instead of 
swallowing, the patient would receive an overdose. Hence only such 
drug, which possesses a substantial margin of safety, can be presented in 
sustained release dosage form. 
2. Improper formulation may result in excessive dosage or the drug release 
may not be complete. 
3. In case of accidental failure of the product effective antidote may be 
difficult to employ. 
4. Sustained release dosage forms are sometimes costlier because of the 
technology involved in producing  the formulation. 
5. Sustained release medications should  not be used with persons known to 
have impaired or erratic gastrointestinal absorbing or kidney troubles. 
6. The physician has less flexibility in adjusting dosage regimens. This 
fixed by dosage form design. 
7. It is difficult to formulate an ideal sustained release dosage form i.e . zero 
order delivery system. 
8. Not all drugs are suitable candidates for formulation as prolong action 
medication. Table lists specific drug characteristics the would preclude 
formulation in per oral sustained release forms. 
 
 1.6 Compounds that are unsuitable for controlled release28,29 
1. Short elimination half- life. 
2. Long elimination half-life 
3. Narrow therapeutic index 
4. Large doses. 
5. Poor absorption 
6. Active absorption 
7. Low or slow solubility. 
8. Time courses of circulating drug levels different to that of 
pharmacological effect.  
9. Extensive first pass clearance. 
Characteristics of drugs unsuitable or oral sustained release forms 
 
 
 
 
 Characteristics       Drugs   
• Not effectively absorbed in the lower   Riboflavin, Ferrous salts  
Intestine 
• Absorbed and excreted rapidly, short                  Penicillin, furasemide 
Biological half –life (<1hr) 
• Long biological half-life (>12hr)     Digoxin, Diazepam 
• Large doses required (>1g)    Sulfonamide ‘ 
• Cumulative action and undesirable                     Phenobarbital,  
effects, drugs with low therapeutic   Digitoxin 
Indices.      
• Precise dosage titrated to individualize   Anti coagulants 
required.       Cardiac  
• NO clear advantage for sustained release   Griseofulvin 
Formulation       
1.7. Designing of controlled release  formulations13,21.  
 From past few yeas considerable important has been given to the 
development of new drug  delivery systems known as controlled release dosage 
formulations. Such interest is base largely on the fact that controlled release drug 
products have established and retained a place in the market based on their 
uniqueness and their clinical advantages in the practice of medicine. 
 
 Controlled release dosage forms are those dosage formulations  designed to 
release an active ingredient at rates, which differ significantly from their 
corresponding conventional dosage forms. The controlled release drug systems are 
aimed at controlling the rate of drug delivery, sustaining the duration of therapeutic 
activity and / or targeting the delivery of drug to a tissue. Drug release from these 
systems should be at a desired rated, predictable and reproducible. 
 
 Controlled release dosage forms have been referred to as delayed action, 
extended action, gradual release  prolonged release, repeat action, slow release, 
sustained release, depot, retard, timed release, targeted, intelligent, novel and 
therapeutic dosage forms.  
 
They provide one or more of the following benefits or advantages 
 
1. Controlled administration of a therapeutic dose at a desirable delivery rate. 
2. Maintenance of drug concentration within an optimal therapeutic range for 
prolonged duration of treatment. 
3. Maximization of efficacy- dose relationship 
4. Reduction of adverse side effects. 
5. Minimization of the needs for frequent dose in take. 
6. Enhancement of patient compliance. 
7. More efficient drug utilization by the body. 
Because of their relatives ease of production and cost, compared with other 
methods  of  sustained or controlled delivery dissolution and diffusion controlled 
systems have classically been of primary importance in oral delivery of 
medication. Most of the SR or CR systems are solids, although a few liquids, 
suspensions have been recently introduces, the classification of such system can be 
as follows. 
 
1. Dissolution controlled systems 
2. Diffusion systems 
3. Dissolution and diffusion controlled systems 
4. Osmotically controlled systems 
5. Ion exchange systems 
 
1.7.1. Dissolution Controlled Systems10,16,36 
 Drug with a slow dissolution rate demonstrates sustaining properties, since 
the release of drug will be limited by the rate of dissolution. This includes 
preparing appropriate salts or derivatives, coating the drug with a slowly dissolving 
material or incorporating it into a tablet with a slowly dissolving carrier. 
 The dissolution process at steady state is described by the Noyes-Whitney 
equation,   dc / dt  =  Kd A(Cs-C) = D/h A (Cs-C)                                                   
Where  
 dc / dt  = Dissolution rate 
Kd = Dissolution rate constant 
D = Diffusion coefficient 
Cs = Saturation solubility of the solid 
C = Concentration of solute in the bulk solution  
 
 
 
1.7.2.Diffusional Systems10,11 
 Diffusion systems are characterized by the release rate of drug being 
dependent on its diffusion through an inert membrance barrier. Usually, this barrier 
is an insoluble polymer. In general two types of subclasses of diffusional systems 
recognized they are,  
1. Reservoir devices 
2. Matrix devices 
Reservoir devices 
 Reservoir devices are characterized by a core of drug the reservoir 
surrounded by a polymeric membrane. The nature of the membrance determisnes 
the rate of release of drug from the system. A schematic description of this process 
as shown in 
 
 
 Fig. 2 Schematic depiction of drug release from a Hydrogel-based reservoir 
delivery system  
 
 
 
The process of diffusion is generally described by Fick’s equation. 
   J = -D dc/dx 
Where,  
 J = flux (amount / area time) 
 D = Diffusion coefficient of the drug in the membrane (area/time) 
 
Advantages: 
1. Zero –order delivery is possible. 
2. Release rate variable with polymer type. 
 
Disadvantages: 
1. Potential toxicity if systems fails. 
2. System must be physically removed from implant sites. 
3. Difficult to delivery high molecular weight compound 
4. Generally increased cost per dosage unit.  
 
Matrix devices 
 It consists of drug dispersed homogeneously throghtout a polymer matrix as 
shown in 
 
Fig.3. Schematic depiction of drug-release from a Hydrogel based matrix delivery 
system  
 
 
Fig.4. Schematic representation of a reservoir diffusion device. Cm (o) and Cm (1) 
represent concentrations of drug at the inside surfaces of the membrane and C (o) 
and C (1) represent concentration in the adjacent regions   
In the model drug in the outside layer exposed to the bathing solution is 
dissolved first and then diffuses out of the matrix. This process continues with the 
interface between the bathing solution and the solid drug moving towards the 
interior. 
 The rate of drug availability is controlled by the rate of penetration of the 
dissolution medium throght the matrix and to the surface of the unit. As the drug 
dissolves, the diffusion path length increases because the polymer matrix is 
insoluble. With proper design of the system, an initial loading dose can be  
provided from the drug particles on or near the surface of the tablet. 
 Once pores have been created, drug release will slow down. Obviously rate 
of release will not be zero- order, as may be desired, because as the diffusion 
length                    
increases, the  rate of dissolution falls, however, if one uses a slowly dissolving 
polymer matrix, where the matrix itself dissolved  at a certain rate so as to keep the 
diffusional length  more or less the same, it can result in a zero-order release. 
 The following equation describes the rate of release of drug dispersed in an 
inert matrix systems, have been derived by Higuchi,  
 
 dM/ dh = C0dh - Cs/2 
 
1.7.3. Dissolution and diffusional controlled release systems10,11,21 
 Strictly speaking, therapeutic systems will never be dependent on dissolution 
only or diffusion only. In practice, the dominant mechanim for release will over 
shadow other  processes enough to allow classification as either dissolution rate – 
limited or diffusion controlled. A typical systems is shown in fig. 
A simple expression describing release from all there of these erodible devices is,  
 
Mt/M  = [1-1-J0t/C0a]n  
Where,  
 n = 3 for a sphere, n=2 for a cylinder and n=1for a slab. 
 a = the radius of a sphere or cylinder or the half height of a slab. 
 Mt = the mass of a drug release at time t. 
 M = the mass released at infinite time. 
 
 
Advantages:  
1. Easier to produce than reservoir devices. 
2. Can deliver high molecular weight compounds 
3. Removal from implant sites is not necessary. 
 
Disadvantages: 
1. Difficult to control kinetics owing to multiple processes of release. 
2. Potential toxicity of degraded polymer must be considered. 
Potential advantage of sustained drug therapy 
1. Avoid patient compliance problems. 
2. Employ less total drug. 
a. Minimize or eliminate local side effects. 
b. Minimize or eliminates systemic side effects. 
c. Reduction in drug activity with chronic use or less potentiation. 
3. Oral controlled release systems 
4. Infusion pumps 
5. Implantable devices (Mini pumps) 
 The two types of the controlling mechanisms ar used in the design of 
controlled release drug delivery systems. 
1. Rate controlling by diffusion process 
The release of drug molecules from the delivery is controlled by the 
molecular diffusion of drug molecules in and / or across the barrier medium within 
or surrounding the delivery systems. In polymer membrane permeations controlled 
drug delivery systems, a drug formulations is totally or partially encapsulated 
within is covered by a rate controlling polymeric membrane with a specific 
permeability. The drug reservoir can be it solid, suspension or solution form. The 
polymeric  membrane can be fabricated from a homogeneous (or a heterogeneous) 
membrane. The encapsulation of drug formulation inside the reservoir 
compartment can be accomplished by injection molding, capsulation, micro 
encapsulation  or other techniques. 
 
2. Rate controlling by modulation process 
In this type of rate– controlled drug delivery, the release of drug  
molecules from the delivery system is slow and very limited by molecular 
diffusion process alone, and can be facilitated by the energy supplied externally or 
activated by some physical processes. The rate of drug release is the modulated by 
the energy or the physical processes applied such as osmotic pressure or 
hydrodynamic pressure or vapour pressure or modulated mechanically or 
magnetically. 
 
Oral controlled release systems 
 The oral route is the most convenient and common mode for administration 
of controlled release systems.  
 The systems have gained importance because of the technological advance 
made in fabrication, which helps in achieving zero order release rates of 
therapeutic moiety. The majority of oral controlled release systems rely on 
dissolution, diffusion, or a combination of both mechanisms to generate slow 
release at drug to the gastro intestinal milieu. Starting with limited data on a drug 
candidate for sustained release such as does, rate constants for absorption  and 
elimination, some elements of metabolism and some physicochemical properties of 
the drug, one can estimate a desired release rate for the dosage form, the quantity 
of the drug needed and a preliminary strategy for the dosage form to be utilized. 
The following are the major types of controlled release systems intended for oral 
use. 
• Coated pellets. 
• Mixed release granules. 
• Erosion-core non-disintegrating tablets. 
• Matrix tablets. 
• Ion exchange and complexation methods. 
• Micro encapsulation and microcapsule. 
• Osmotically controlled oral preparations. 
 
1.9 Type of prolonged action dosage forms45 
 there are many different types of prolonged action products. Balland and 
nelson discussed this subject exhaustively and listed many examples; Edward 
stempel discussed the various methods of prlonging the drug absorption and thus 
drug action. John G. Wagner listed out the mechanism and types of construction 
of oral prolonged action dosage form.  W.A. Ritschel discussed various types of 
pre-oral and parenteral prolonged action dosage forms. The techniques used for 
oral and parenteral prolonged action preparations are listed below. 
• Barrier coating 
• Embedding the drug in slowly erodible matrix 
• Skeleton type preparations.  
• Repeat action preparations. 
• Ion-exchange resin beads. 
• Hydrophilic matrix / diffusion controlled matrix 
• Polymer resin beads. 
 
 
1.10. Components of controlled release devices4,46 
 A controlled release matrix system consists of the active agent and the 
polymer matrix or matrices that regulate its release. In selecting polymeric matrix, 
the following design criteria should be considered.  
• Molucular weight and chemical functionality of the polymer must allow the 
proper diffusion and release of the specific active agent. 
• Polymer functional groups should not react chemicals with the active agent. 
• The polymer and its degradation products must be non-toxic to the 
environment. 
• The polymer must be easily manufactured or fabricate into the desired 
product and should allow incorporation of large amounts of actives agents in 
the products without  sacrificing its mechanical properties. 
• The cost of the polymer should not be expensive which would cause a 
sustained release product to be non competitive. 
• The various controlled release technologies cover a very broad spectrum of 
drug dosage forms. Controlled release technologies include, but are not 
limited to physical systems and chemical systems. 
• Physical systems include, but are not limited, to reservoir with rate 
controlling membranes, such as microencapsulation, macroencapsultion and 
membrane systems; reservoir systems without rate-controlling membrane, 
such as hollow fiber, ultra microporous cellulose triacetate, and porous 
polymeric, or elastomeric matrices (e.g. nonerodible, polymerice, or 
elastomeric matrices, erodible, environmentral agent ingressions and 
degradable); laminated structures, including reservoir layers chemically 
similar or dissimilar to outer control layer, and other physical methods, such 
as sosmotic pump, or adsorption onto ion-exchange resins. 
• Chemical systems include systems,  but are not limited to chemical erosion 
of polymer matrices (e.g. heterogeneous, or homogenesous erosion), or 
biological erosion of a polymer matrix (eg heterogeneous , or homogeneous) 
• Controlled release drug delivery systems may also be categorized under their 
basic technology areas, including but not limited to, rate-preprogrammed 
drug delivery systems, activation-modulated drug delivery and site-targeting 
drug delivery system.  
• In rate- preprogrammed drug delivery systems, release of drug molecules 
from the delivery systems, “preprogrammed” at specific rate profiles. This 
may be accomplished by system design, which controls the molecular 
diffusion of drug molecules in and /or across the barrier medium within or 
surrounding the delivery systems. Fick’s law of diffusion are often followed. 
• In a site –targeting controlled release drug delivery system, the drug system 
targets the active molecule to a specific site or target tissue or cell. 
• While a preferable mode of controlled release drug delivery will be oral, 
other modes of delivery of controlled release compositions according to this 
invention may be used. 
• These include mucosal delivery, nasal  delivery, ocular delivery, transdermal 
delivery, parenteral controlled release delivery, vaginal delivery, and 
intrauterine delivery.  
• Another type of useful oral controlled release structure is a solid dispersion. 
A solid dispersion may be defined as a dispersion of one or more active 
ingredients in an inert carrier or matrix in the solid state prepared by eh 
melting (fusion), solvent, or melting –solvent method. 
1.11. Matrix System10,35,42 
One of the least complicated approaches to the manufacture of sustained  
release dosage forms involves the direct compression of blends of drug, retardant 
material and additives to form a tablet in which drug is embedded in a matrix of 
the retardant. Alternatively drug blends may be granulated prior to compression. 
The following table identified example of the three classes or retardant  material 
used to formulate matrix tablets, each class demonstrating a different approach to 
the matrix concept.  
 The first class consists or retardant that forms insoluble or “skeleton” 
matrices, the second class represents water-soluble materials that are potential 
erodible and the third class consists of polymers that form hydrophilic matrices. 
 
 
 
 
 
 
 
Table -1 
Materials used as retardants in matrix tablets formulations 
    
Matrix Characteristics   Material 
1.Insoluble, Inert Polyethylene, Polyvinyl chloride, Methyl 
acrylate,  Methacrylate co-polymer, Ethyl 
cellulose  
2. Insoluble, Erodible Carnauba wax, Stearyl alcohol, stearic acid, PEG. 
3. Hydrophilic Methyl cellulose, (400cps, 4000cps), Hydroxy 
ethyl Cellulose, HPMC (60HG, 90HG, 25cps, 40 
00cps, 1500cps), Sodium CMC, Soduum alginate, 
carboxyl-Polyethylene.  
 
 Insoluble inert polymers such as polyethylene, polyvinylchloride and 
acrylate co-polymers have been used as the basic material for may marketed 
formualations. Tablets prepared from these materials are designed to be suggested 
instant the not break part in the GI tract. Tablets may be directly compressed from 
mixture of drugs and ground polymer. However if ethyl cellulose is uded as the 
matrix former, a (wet) granulation procedure using ethanol can be employed. The 
rate limiting step in controlling release from these formulations is liquid 
penetration into the matrix unless channeling (wetting) agents are included to 
promote the permeation of the polymer matrix by water, allows drug dissolution 
and diffusion from the channel created in the matrix. 
 
 
 
 Formulations should be designed so that pore diffusion becomes rate 
controlling release is defined by equation 1,2. Drug bioavailability which is 
critically dependent on the drug. Polymer ratio, may be modified by inclusion of 
diluents such as lactose in place of polymer in low-milligram potency formlaitons. 
 Higuchi has provided the theroretic basis for defining drug release from inert 
matrices. The equation describing drug release form the planner surface of an 
insoluble matrix is.  
 Q = [[D  Cg / T] [2A-  Cs] t] ½ ----------(1) 
   
Q is the amount of drug released per unit, surface after time t. 
E is porosity of the matrix. 
D is the diffusion co-efficient of the drug in the elution medium 
T is the tortuosity of the matrix 
Cs is the solubility of the drug in the elution medium 
A is initial loading dose of drug in the matrix. 
Drug release in triggered by penetriaon of eluting media into the matrix 
dissolving the drug, there by creating channels through which diffusion take place.  
A high tortuosity means that the effective averages diffusion path is large. 
The porosity term takes into account the space available for drug dissolution, an 
increased porosity results in increase drug release. Both porosity and tortuosity are 
functions of the amount of dispersed drug, the physico-chemical properties of the 
matrix, and dispersion charactestics of the drug in the matrix  
If the drug is freely soluble in the elution medium that is Cs >> A, such that 
the dissolution rate is rapid, then equation (2), which describes the release or drug 
from a solution entrapped in an insoluble  matrix applied. 
 Q = 2A (Dt / TIT) ½  -----------(2)   
Release rate is directly proportional to the amount of dispersed drug A; it is 
proportional to A ½ for insoluble drug if 2A = Cs These expressions predict the 
plots of Q Vs t ½ be liner. 
 
Release of water soluble drugs, however should be unaffected by the amount 
of liquid pH value, enzyme content and other physical properties of digestive 
fluids, unless the drug is in a salt form that precipitates within the matrix pores on 
dissolution when penetrated by acidic or basic media.  
 
1.12.  Biopharmaceutical Considerations3,36,48 
The BCS is a scientific framework for classifying drug substances base on 
their aqueous and intestinal permeability. When combined with the dissolution of 
the drug product, the BCS takes into account there major factor that govern the rate 
and extent of drug absorption from IR solid oral dosage forms: dissolution 
solubility, and intestinal permeability. According to the BCS, drug substances are 
classified as follow 
  Class 1 :  High Solubility  -  High Permeability 
  Class 2 : Low Solubility -  High Permeability 
  Class 3 : High Solubility -  Low Permeability 
  Class 4 : Low Solubility - Low Permeability 
A.Solubility 
 The solubility class boundary is base on the highest dose strength of an IR 
product that is the subject of  a bioaiver request, a drug substance is considered 
highly soluble when the highest does is soluble in 250 ml or less of aqueous media 
over the pH range of 1-7.5. the voluve estimate of 250 ml is derived from typical 
BE study protocols that prescribe administration of a drug product to fasting 
volunteers with a glass (about 8 ounces) of water. 
 
B.Permeability 
 The permeability  class boundary is based indirectly on the extent of 
adsorption (fraction of dose absorbed, not systematic BA) of a drug substance in 
humans and directly on measurements of the rate of mass transfer across human 
intestinal membrane. Alternatively, nonhuman systems capable of predicting the 
extent to be 90% or more of an administered dose base on a mass balance 
determination or a comparison to an intravenous reference dose. 
C.Dissolution  
    In this guidance, an IR drug product is considered rapidly dissolving when 
no less than 85% of labeled amount of the drug substance dissolved within 30 
minutes, using U.S. Pharmacoperia (USP) Apparatus I at 100 rpm (or Apparatus II 
at 50 rpm) in a volume of 500 ml or less in each of the following mediaa: (1) 0.1N 
HCL or Simulated Gastric Fluid USP without enyzmers (2) a pH  4.5 buffer, (3) a 
pH 6.8 buffer or Simulated Intestinal   Fluid USP without enzymes.  
 
  The success of  a therapy depends on selection of the t appropriated delivery 
systems as much as it depend on selection on the drug itself . A dosage form, 
whether conventional of CR, can have a significant effect on bioabailability and 
makes a difference between success and failure therapy. 
 
 For ocnvetional oral dosage  forms, a major concern is bioavailability of a 
drug. Selection of dosage forms is base on how rapidly and completely drug is 
available. Both from institution as well as experimental obesrvaiton, systemic 
availability of a drug is maximum from an aqueous solution and minimum from a 
coated tablet, with suspension, capsule and tablet, showing intemediated 
bioavailabilities in that order. Deviation from this rule are some times observed. 
The picture however is different of CR formulations, where one rarely has a choice 
of solution or suspension dosage for not only bioavailability but also uniformity of 
drug input into the body . 
12. Biopharmaceutical considerations  
 The rate and extent of drug absorption from CR dosage forms is determined 
by the rate of release from the dosage form. This is based on the assumption that 
absorption form the entire GI tract is efficient enough not be rate limiting. 
Although a common observation is less than from a conventional dosage form. 
Possible explanations for these observations are as follows.  
 
 
 
•   Drug release is not complete from a  CR  formulations specially for those 
designed release drug for period longer that 6 hr at a low release rate. 
•   There is a greater degree of reabsorpiton degradation and metabolism in the 
GI tract particularly for storable process or colonic delivery systems. 
•    First –pass metabolism for CR formulations may be higher.  
•    Drug release may be at a site of poor absorption, eg. The colon. 
•    Fewer dissolution media are available for CR dosage forms, especially in 
the terminal ileum. 
•    There is differential absorption from the GI tract i.e. drug absorption takes 
place in a limited area. 
•   GI residence of the dosage form may be variable and unpredictable. 
 
As with conventional dosage forms, considerable differences in  
performances among different CR products of the same drugs are frequently  
observed. This will result in considerable variations in plasma drug profiles  for 
similar doses. 
Drug devices that are designed to stay in a particular segment of the GI tract 
eg. Bioadhesive systems have delayed gastric emptying and one must take into 
account the stability of the drug in that environment. Degradation due to pH or 
enzymes may reduce bioavailability of such dosage forms. Also single-units 
intended to stay at the pylorus or ileo-cecal junction may release enough drugs in 
their immediate vicinity to cause local toxicity or irrition. Design must also 
account for possible bacterial degradation and variable and poor absorption from 
the colon and rectum. 
1.13.Pharmacokinetics   consideration in the design of sustained release drug 
delivery systems. 
  The objective in designing sustained release systems to deliver drug at a rate 
necessary to achieve and maintain constant drug blood level. Attainment of an 
absorption rate equivalent of the drug in the body is the principle underlying the 
design of prolonged action dosage forms. To design and fabricate an effective 
sustained  release dosage forms.The fraction of the total dose into the 
gastrointestinal tract called “loading dose “ is consistent with the drugs intrinsic 
availability  of absorption. The remaining fraction of the total dose is then release 
as rapidly as required for some desirable period of time. Thus the rate of drug 
absorption from the maintenance dose into the body should be equivalent to rate of 
drug eliminated the body by all processes, the time  for which desired intensity of 
pharmacological response is required.   
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
2. REASONS FOR STUDY 
 
 
 Ondansetron Hydro chloride  is short acting drug for management of nausea 
and vomiting. It is absorbed from GIT and peak plasma concentration have 
occured 1 to 2 hours after dosing. It undergoes extensive first pass metabolism in 
the liver and is excreted mainly in the urine as inactive metabolites. 
 
 For sustained or controlled release it will helps in reduction of its side effects 
due to high concentration at the absorption site. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3. LITERATURE SURVEY 
 
 Barry, et al (Us Patent no:  5,055,306; 1991) prepared sustained release 
formulations of 5HT3 antagonist substance presented in the form of a tablet, said 
tablet comprising sufficient granules to provide a predetermined dose or number of 
doses of the  pharmacologically active substance and effervescent or water- 
dispersible ingredients, each of said granules having a diameter of preferably 
between 0.5 and 2.5 mm and comprising: a) a core comprising one or more 
phrmacologically active substances and preferably one or more excipients; and b) 
and coating covering substantially the whole surface of the core and  comprising 
100 parts of a water insoluble but water swellable acrylic polymer 20 to 70 parts of 
a water     soluble and hydroxyl and cellulose   derivative, the weight of the coating 
being form 2 to 25 % of the weight of the core. A method for preparing this 
effervescent of  water- dispersible tablet formulations is also core. A method for 
preparing this effervescent of water- dispersible tablet formulation is also provided. 
Such formulations enable large dosages in sustained – release form to be more 
easily administered to patients. 
 
 Zhang Y, Huang G, Han J, Yu P (2006);  prepared the ondansetron 
hydrochloride sustained – release tablets and studied the influencing factors, on the 
ondansetron hydrochloride sustained –release tablets, using the  
hydroxypropylmethylcellulose (HPMC) as the matrix material. They investigated 
methods, the alcohol content in adhesives, and the pH of the dissolving solution on 
the release of ondansetron hydrochloride from sustained release tablets. One the 
basis of pharmaceutical formulation  studies, the best formulation and preparation 
methods were screened out according  , ondansetron hydrochloride sustained – 
release tablets had good drug release behavior for in 12 h in vitro studies. To 
prepare the formulation from  drug and polymer ratio for 1:2 ,1:3.  and evaluation  
by  the    dissolution at phosphate buffer PH   
 
6.8 in good drug release . 
 Landau et al (US patent no: 7,094, 786; 2006). Developed the method for 
the treatment of nausea and vomiting in a patient suffering from nausea and 
vomiting by administering 4-(2-fluorophenyl)-6 methyl12-(1-piperazinyl) thieno 
[2,3-D] pyrimidine. i..e. the use of 5-HT. sub .3 receptor antagonists such as 
ondansetron, granisetron and tropisetron has been shown to be less effective for 
delayed nausea and vomiting than for acute symptoms. In addition, efficacy of the 
5-HT. sub. 3 receptor antagonists appears to be less pronounced for moderate 
emetogenic chemotherapy regimens than for cisplatin-containing regimens. 
Further, control over nausea appears to be significantly less than control over 
vomiting, further, the efficacy of the agents appears to diminish across repeated 
days and across repeated chemotherapy cycles.  
 
 Srinivas Reddy et al. (2003)  The objective of the present study was to 
develop once-daily sustained-release matrix tablets of nicorandil, a novel 
potassium channel opener used in cardiovascular diseases. The tablets were 
prepared by the wet granulation method. Ethanolic solutions of ethylcellulose 
(EC), Eudragit RL Trang Web nay coi cung hay, vao coi the -100, Eudragit RS-
100, and polyvinylpyrrolidone were used as granulating agents along with 
hydrophilic matrix materials like hydroxypropyl methylcellulose (HPMC), sodium 
carboxymethylcellulose, and sodium alginate. The results of dissolution studies 
indicated that formualtion F-I (drug –to-HPMC, 1:4; ethanol as granulating agent) 
could extend the drug release up to 24 hours. In the further formulation 
development process, F-IX (drug-to-HPMC, EC 4% wt/vol as   granulating agent), 
the most successful formulation of the study, exhibited satisfactory drug release in 
the initial hours, and the total release pattern was very close to the theoretical 
release profile. All the formulations (except F-IX) exhibited diffusions-dominated 
drug release. The mechanism of drug release from F-IX was diffusion coupled with 
erosion.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4. AIM & OBJECTIVE 
 
 The main objective of this work is to investigate the possibility of sustained 
release dosage forms for the drug in ondansetron hydrochloride  by usings different 
grades of HPMC polymers by diffusin controlled matrix. 
 
 For this  investigation in  various formulation (formulation I-formulation –V 
)at different polymers for HPMC K4 M, HPMC K15 M, HPMC K100LVP  were 
made by using drug 4 mg.  
 
 The aim of this study to formulate and evaluate the release pattern of drug 
from sustained release matrix tablets. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5. PLAN OF WORK 
 
1.Preformulation study 
2.Dose calculation  
3. Preparation of sustained release tablets using the polymer at various 
concentrations.  
4.Evaluation of Physical parameters 
a. Weight variation  
b. Hardness 
c. Thickness 
d. Friability 
 
5.Invitro evaluation of tablets  
6.Assay 
7.Accelerated stability studies of tablet. 
 
 
6. Drug and Excipeints Profile 
 
6.1 Drug Profile19,20,33,35,38  
 
The active ingredient ondansetron hydrochloride tablets is ondansetron 
hydrochloride(HC1) as the dihydrate, the racemic form of ondansetron and a 
selective blocking agent of the serotonin  5 -HT3 receptor type. 
 
Structural Formula: 
 
                  
 
  .HCI.2H2O 
 
Chemical Name: (±) 1, 2, 3, 9-tetrahydro-9-methyll3 [(2methyl – 1 H- 
           imidazol- 1-yl)methyl]-4H-carbazol -4-one,monohy  
                               droch1oride, dihydrate.  
 
Molecular Formula: C 18H 19N30 .HC12H20. 
 
Molecular Weight: 365.9 
 
Colour: white to off-white powder. 
Solubility: Sparingly soluble in water and in alcohol: Soluble in Methanol, slightly 
soluble in Methylene chloride. 
 
Clinical Pharmacology 
 
Pharmacodyamics 
 
Ondansetron is a selective 5-HT3 receptor antagonist. While its mechanism 
of action has not been fully characterized, ondansetron is not a dopamine - receptor 
antagonist. Serotonin receptors of the 5 -HT3 type are present both peripherally on 
vagal nerve terminals and centrally in the chemoreceptor trigger zone of the area 
postrema. It is not certain whether ondansetron’s antiemetic action is mediated 
centrally, peripherally, or in both sites. However, cytotoxic chemotherapy appears 
to be associated with release of sero tonin from the enterochromaffin cells of the 
small intestine. In humans, urinary 5 -HIAA (5-hydroxyindoleacetic acid) 
excretion increases after cisplatin administration in parallel with the onset of 
emesis. The released serotonin may stimulate the vagal afferents through the 5-
HT3 receptors and initiate the vomiting reflex. 
 
In normal volunteers, single intravenous doses of 0.15 mg/kg of ondansetron 
had no effect on esophageal motility, gastric motility, lower esophageal sphincter 
pressure, or small intestinal transit time. Multiday administration of ondansetron 
has been shown to slow colonic transit in normal volunteers. Ondansetron has no 
effect on plasma prolactin concentrations. 
Ondansetron does not alter the respiratory depressant effects produced by 
alfe ntanil or the degree of neuromuscular blockade produced by atracurium. 
Interactions with general or local anesthetics have not been studied.  
 
Pharmacokinetics 
 
Ondansetron is well absorbed from the gastrointestinal tract and undergoes 
some first-pass metabolism. Mean bioavailability in healthy subjects, following 
administration of a single 8 mg tablet, is appi oximately 56% 
 
Ondansetron systemic exposure does not increase proportionately to dose. 
AUC from a 16 mg tablet was 24% greater than predicted from an 8 mg tablet 
dose. This may reflect some reduction of first-pass metabolism at highei oral doses 
Bioavailability is also slightly enhanced by the presence of food but unaffected by 
antacids. 
 
Ondansetron is extensively metabolized in humans, with approximat ely 5% 
of a radiolabeled dose recovered as the parent compound from the urine. The 
primary metabolic pathway is hydroxylation on the indole ring followed by 
subsequent glucuronide or sulfate conjugation. Although some nonconjugated 
metabolites have pharmacologic activity, these are not found in plasma at 
concentrations likely to significantly contribute to the biological activity of 
ondansetron. 
 
In vitro metabolism studies have shown that ondansetron is a substrate for 
human hepatic cytochrome P-450 enzymes, including CYP1A2, CYP2D6, and 
CYP3A4. In terms of overall ondansetron turnover, CYP3A4 played the 
predominant role. Because of the multiplicity of metabolic enzymes capable of 
metabolizing ondansetron, it is likely that inhibition or loss of one enzyme (e.g., 
CYP2D6 genetic deficiency) will be compensated by others and may result in little 
change in overall rates of ondansetron elimination.  
 
Ondansetron elimination may be affected by cytochrome P-450 inducers. In 
a pharmacokinetic study of 16 epileptic patients maintained chronically on 
CYP3A4 inducers, carbamazepine, or phenytoin, reduction in AUC, C max, and 
T1/2 of ondansetron was observed 1. This resulted in a significant increase in 
clearance. However, on the basis of available data, no dosage adjustment for 
ondansetron is recommended in humans, carmustine, etoposide, and cisplatin do 
not affect the pharmacokinetics of ondansetron. 
 
Gender differences were shown in the disposition of ondansetron given as a 
single dose. The extent and rate of ondansetron’s absorption is greater in women 
than men. Slower clearance in women, a smaller apparent volume of distribution 
(adjusted for weight), and higher absolute bioavailability resulted in higher plasma 
ondansetron levels. These higher plasma levels may in part be explained by 
differences in body weight between men and women. It is not known whether 
these gender –related differences were clinically important. 
 
Indications and Usage for Ondansetron 
 
Prevention of nausea and vomiting associated with highly emeto genic 
cancer chemotherapy, including cisplatin 50 mg/rn 2 
 
 Prevention of nausea and vomiting associated with initial and repeat courses 
of moderately em the cancer chemotherapy. 
 
Prevention of nausea and vomiting associated with radiotherapy in patient s 
receiving either total body irradiation, single high-dose fraction to the abdomen, or 
daily fractions to the abdomen. 
 Prevention of postoperative nausea and/or vomiting. As with other 
antiemetics. routine prophylaxis is not recommended for patients in whom there is 
little expectation that nausea and or vomiting will occur postoperatively. In 
patients where nausea and/or vomiting must be avoided postoperatively, 
ondansetron hydrochloride tablets are recommended even where the incidence of 
postoperative nausea and/or vomiting is low. 
 
Contraindications 
 
Ondansetron hydrochloride tablets are contraindicated for patients known to 
have hypersensitivity to the drug. 
 
 
 
 
Warnings 
 
Hypersensitivity reactions have been reported in patients who have exhibited 
hypersensitivity to other selective 5 -HT3 receptor antagonists. 
 
Precautions 
General 
 
Ondansetron is not a drug that stimulates gastric or intestinal peristalsis. It 
should not be used instead of nasogastric suction. The use of ondansetron in 
patients following abdorni nal surgery or in patients with chemotherapy-induced 
nausea, and vomiting may mask a progressive ileus and/or gastric distension. 
 
Rarely and predominantly with intravenous ondansetron, transient ECG 
changes including QT interval prolongation have been reported. 
Drug Interactions 
 
Ondansetron does not itself appear to induce or inhibit the cytochrome P -
450 drug- metabolizing enzyme system of the liver. Because ondansetron is 
metabolized by hepatic cytochrome P-450 drug-metabolizing enzymes (CYP3A4, 
CYP2D6, CYP 1A2), inducers  or inhibitors of these enzymes may change the 
clearance and, hence, the half-life of ondansetron. On the basis of available data, 
no dosage adjustment is recommended for patients on these drugs. 
 
 
Phenytoin, Carbamazepine, and Rifampicin 
 
In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, 
carbamazepine, and rifampicin), the clearance of ondansetron was significantly 
increased and ondansetron blood concentrations were decreased. However, on the 
basis of available data, no dosage adjustment for ondansetron is recommended for 
patients on these drugs3,4 
Tramadol 
 
Although no pharmacokinetic drug interaction between ondansetron and 
tramadol has been observed, data from 2 small studies indicate that ondansetron 
may be associated wit h an increase in patient controlled administration of 
tramadol8,9 
 
Chemotherapy 
 
Tumor response to chemotherapy in the P-388 mouse leukemia model is not 
affected byondansetron. In humans, carmustine, etoposide, and cisplatin do not 
affect the pharmacokinetics of ondansetron. 
 
In a crossover study in 76 pediatric patients, I.V. ondansetron did not 
increase blood levels of high-dose methotrexate. 
 
 
 
 
 
Use in Surgical Patients 
 
The coadministration of ondansetron had no effect on the pharmacokinetics 
and pharmacodynamics of temazepam. 
 
Carcinogenesis, Mutagenesis, Impairment of Fertility 
 
Carcinogenic effects were not seen in 2 -year studies in rats and mice with 
oral ondansetron doses up to 10 and 30 mg/kg/day, respectively. Ondansetron was 
not mutagenic in standard tests for mutagenicity. Oral administration of 
ondansetron up to 15 mg/kg/day did not affect fertility or general reproductive 
performance of male and female rats. 
 
Pregnancy 
 
Teratogenic Effects 
 
Pregnancy Category B. Reproduction studies have been perform ed in 
pregnant rats and rabbits at daily oral doses up to 15 and 30 mg/kg/day, 
respectively, and have revealed no evidence of impaired fertility or harm to the 
fetus due to ondansetron. There are, however, no adequate and well-controlled 
studies in pregnant women. Because animal reproduction studies are not always 
predictive of human response, this drug should be used during pregnancy only if 
clearly needed. 
 
 
 
Geriatric Use 
Of the total number of subjects enrolled in cancer chemotherapy -induced 
and postop erative nausea and vomiting in US - and foreign-controlled clinical 
trials, for which there were subgroup analyses, 938 were 65 years of age and over. 
No overall differences in safety or effectiveness were observed between these 
subjects and younger subject s, and other reported clinical experience has not 
identified differences in responses between the elderly and younger patients, but 
greater sensitivity of some older individuals cannot be ruled out.).  
 
Adverse Reactions 
 1. Difficulty in breathing, wheezing, shortness of breath 
 
2. Fast or irregular heart beat. 
 
3. Constipation or diarrhoea. 
 
4. Headache 
 
5. Dry mouth 
 
6. Stomach pain 
 
7. Skin rash, itching, swelling of the face, tongue , throat, hands and feet. 
8. Fever and chills. 
 
Drug Abuse and Dependence 
 
Animal studies have shown that ondansetron is not discriminated as a 
benzodiazepine nor does it substitute for benzodiazepines in direct addition studies. 
 
Overdosage 
 
There is no specific antidote for ondansetron overdose. Patients should be 
managed with appropriate supportive therapy. Individual intravenous doses as large 
as 150 mg and total daily intravenous doses as large as 252 mg have been 
inadvertently administered without significant adverse events. These doses are more 
than 10 times the recommended daily dose. 
 
In addition to the adverse events listed above, the following events have 
been described in the setting of ondansetron overdose: “Sudden blindness” 
(amaurosis) of 2 to 3 minutes’ duration plus severe constipation occurred in 1 
patient that was administered 72 mg of ondansetron intravenously as a single dose. 
Hypotension (and faintness) occurred in a patient that took 48 mg of ondansetron 
hydrochloride tablets. Following infusion of 32 mg over only a 4-minute period, a 
vasovagal episode with transient second -degree heart block was observed. In all 
instances, the events resolved completely. 
 
 
 
Ondansetron Dosage and Administration 
 
1) Prevention of Nausea and Vomiting Associated With Highly Emetogenic 
Cancer 
Chemotherapy 
 
The recommended adult oral dosage of ondansetron hydrochioride tablet is 
24 mg given as three 8 mg tablets administered 30 minutes before the start of 
single -day highly emetogenic chemotherapy, including cisplatin 50 mg/m2. 
Multiday, single-dose administration of a 24 mg dosage has not been studied. 
 
Pediatric Use 
There is no experience with the use of a 24 mg dosage in pediatric patients. 
Geriatric Use 
The dosage recommendation is the same as for the general population. 
 
2) Prevention of Nausea and Vomiting Associated With Moderately 
Emetogenic Cancer Chemotherapy 
 
The recommended adult oral dosage is one 8 mg ondansetron hydrochloride 
tablet given twice a day. The first dose should be administered 30 minutes before 
the start of emetogenic chemotherapy, with a subsequent dose 8 hours after the 
first dose.one  8 mg ondansetron hydrochloride tablet should be administered twice 
a day (every 12 hours) for1 to 2 days after completion of chemotherapy. 
Pediatric Use 
 
For pediatric patients 12 years of age and older, the dosage is the same as for 
adults. For pediatric patients 4 through 11 years of age, the dosage is one 4 mg 
ondansetron hydrochloride tablet given 3 times a day. The first dose should be 
administered 30 minutes before the start of emetogenic chemotherapy, with 
subsequent doses 4 and 8 hours after the first dose. One 4 mg ondansetron 
hydrochloride tablet should be administered 3 times a day (every 8 hours) for 1 to 
2 days after completion of chemotherapy. 
 
Geriatric Use 
 
The dosage is the same as for the general population. 
 
 
 
  
 
 
 
 
 
 
 
 
6.2 Additives used in formulation of Ondansetron Hydrochloride sustained 
release tablets34,41,43,45. 
 
1. HYDROXYPROPYL METHYL CELLULOSE 
1. Nonproprietary Name 
BP : Hypromellulose 
JP : Hydroxyprophyl methyl cellulose 
PhEur : Methylhydroxy prophyl cellulosum 
USP : Hydroxypropyl methyl cellulose 
Synonyms 
 Benecel MHPC; Cellulose, Hyroxypropyl methyl ether; E464; HPMC; 
Methocel; Methycellulose propylene glycolether; methyl Hydroxypropyl cellulose, 
Metolose; Pharmacoat,  
 
Chemical Name and CAS Registry Number 
 Cellulose, 2- Hydroxypropyl methyl ether. 
 
Empirical Formula    Molecular weight 
O-methylated and O-    10,000-15,00,000 
(2-hydroxypropylated cellulose)   
 
Functional Category 
 Coating agent; film former; rate-controlling polymer for sustained release; 
stabilizing agent; suspending agent; tablet binder; viscosity – increasing agent.  
 
 
 
Applications is Pharmaceutical Formulation or Technology 
 Hydroxyl propyl methylcellulose is widely used in oral and topical 
pharmaceutical formulation. 
 
 In oral products, hydroxypropyl methylcellulose in primary used as a tablet 
binder, in film coating, and as an extended-release tablet matrix. Concentrations of 
between 2-5% w/w may be used as a binder in either wet or drug granulation 
processes. High viscosity grades may be used to retard the release of drugs from a 
matrix at levels 10-80% w/w  in tablet and capsule, depending upon the viscosity 
grades concentrations between2-20% w/w are used as film-forming solutions to 
film coat tablets. Lower viscosity grades are used in aqueous film-coating solutions 
while higher viscosity grades are used with organic solvents. 
 
 Hydroxypropyl methylcellulose is also used as a suspending and thickening 
agent in topical formulations, particularly ophthalmic preparations. Compared with 
methylcellulose, hydroxypropyl methycellulose produces solutions of greater 
clarity, with fewer undispersed fibres present, and is therefore preferred in 
formulations for ophthalmic use. Concentrations of between-  0.45-1.0% w/w 
made be added as a thickening agent to vehicles for eye drops and artificial tear 
solutions.  
 
 Hydroxypropyl methylcellulose is also used as an emulsifier, suspending 
agent, and stabilizing agent in topical gels and ointments. As a protective colloid, it 
can prevent droplets and particles from coalescing or agglomerating, thus 
inhibiting the formulation of sediments. 
 
 In addition, hydroxypropyl methylcellulose is used in the manufacture of 
capsules, as an adhesive in plastic bandages and as a wetting agent for hard contact 
lenses. It is also widely used in cosmetics  and food products.  
 
Applications   Table-2 
Sr. No Use Conc% w/w 
1) Binder 2-5% 
2) Film-former 2-20 % 
3) Thickening agent 0.45-1.0 % 
 
Viscosity 
Table-3 
Sr. no Grades Nominal  (µm) Viscosity (m Pas) 
1 K 100LVP 100 80-120 
2 K 4 M 4000 3000-5600 
3 K 15 M 15000 12000-21000 
 
Description  
 Hydroxypropyl methylcellulose is an odorless and tasteless, white or 
creamy-white colored fibrous or granular powder. 
 
 
 
 
Typical Properties 
Acidity /alkalinity: PH=5.5-8.0 for a 1% w/w aqueous solution 
Density (bulk): 0.341 g/cm3 
Density (tapped) : 0.557 g/cm3 
Density (true) : 1.326g/cm3 
Melting point; Browns at 190º-2000C; chars at 225ºC-2300C. Glass transition 
temperature is 170ºC-1800C. 
Solubility 
 
 Soluble in cold water, forming a viscous colloidal solution; practically 
insoluble in chloroform, ethanol (95%), and ether, but soluble in mixtures of 
ethanol and dichloromethame, mixtures of methanol and dichloromethane, and 
mixtures of water and alcohol, certain grades of hydroxpropyl methylcellulose are 
soluble in aqueous acetone solutions, mixtures of dichloromethane and proan -2-
01, and other organic solvents. 
 
Stability and storage conditions 
 Hydroxypropyl methylcellulose powder is a stable material although it is 
hygroscopic after drying. 
 
Incompatibilities 
 Hydroxypropyl methylcellulose is incompatible with some oxidizing agents. 
Since it is nonionic, hydroxypropyl methylcellulose will not complex with metallic 
salts or ionic organics to form insoluble precipitates. 
 
 
 
2. MICROCRYSTALLINE CELLULOSE (AVICEL PH 101) 
Synonyms : Avicel PH; Emcocel; Pharmacel. 
Formula  : (C6H10O5)n -36000 
   Where n = 220 
 
Funtional Category : Tablet and Capsule diluent, Disintegerant. 
Description : White, odourless, tasteless, crystalline powder composed of porous 
particle. It is commercially available in different particle sizes and moisture grades 
that have different properties and applications.  
 
Typical Properties : LOD -6.0% to 7.0% 
        Bulk Density   = 0.32 g/cm3 
        Tapped Density = 0.45 g/cm3 
        Melting Point = 260ºC-270C 
       Moisture Content = Less than 5 % w/w  
  Particle size distribution: Mean particle size is 20-200 µm Solubility :  
slightly soluble in 5 % w/v NaOH solution ; practically insoluble in water, dilute 
and most organic solvents.  
Table-4 
Particle size analysis  Grade Nominal particle size 
(µm) Mesh size Amount retained 
% 
 
Moisture  
Content 
(%) 
Avicel PH 
101 
50 60 
200 
1.0 
30.0 
5.0 
 
 
Applications: 
Table-5 
Sr.No Use  Conc.% 
1) Adsorbent 20-90 
2) Anti-adherent 5-20 
3) Capsule binder/diluents 20-90 
4) Tablet disintegerant 5-15 
5) Tablet binder/diluents 20-90 
 
3. STARCH – 1500 
Nonproprietary  Names 
 
PhEur: Strach, pregelatinized 
USP; Pregelatinized Starch 
 
Synonyms 
 Compressible starch. Instastarch, Lycatab PGS, Pharma-Gel, Prejel, Sepistab 
ST 200, Starch 1500. 
 Chemical Name of CAS Registry Number 
 Pregelatinized starch (9005-25-8) 
 
Empirical  Category 
 (C6H10O5)n  
Where n = 300-1000 
 
 
Functional Category 
 Tablet and capsule diluent, tablet and capsule disintegrant ,tablet binder. 
 
Applications in Pharmaceutical formulation or Technology 
 Pregelatinized starch is a modified starch used in oral capsule and tablet 
formulations as a binder, diluent, and disintegrant. 
 
 In comparison to starch, grades of pregelatinized starch may be produced 
with enhanced flow and compression characteristics such that the pegelatinized 
material may be used as a tablet binder in dry compression processes. In such 
processes pregelatinized starch is self lubricating. Pregelatinized starch may also 
be used in wet granulation processes. 
 
Table-6 
Use Concentration (%) 
 
Diluent  
  
Tablet binder (direct compression)
  
Tablet binder (wet granulation)  
 
Tablet disintegent 
 5-75 
5-20 
5-10 
5-10 
 
 
  
 
Description 
 Pregelatinized starch occurs as a moderately coarse to fine, white to off-
white colored powder, it is odorless and has a slight characteristic taste. 
 
Typical Properties 
 
Acidity /alkalinity ; PH=4.5-7.0 for a 10% w/v aqueous solution. 
Density (bulk): 0.586g/cm3 
Density (tapped); 0.879g/cm3 
Density (true): 1.516g/cm3 
Angle of repose : 40.70 
Flowbility : 18-23% 
 
Solubility 
 
Practically insoluble in organic solvents, slightly soluble to soluble in cold 
water, depending upon the degree of pregelatinization. 
 
Stability and storage conditions 
Pregelatinized starch is a stable, through hygroscopic material, which should 
be stored in a well-closed container in a cool, dry, place. 
 
 
 
 
4. LACTOSE MONOHYDRATE 
Synonyms: Pharmatose, SorboLac, Super-Tab, Tablettose, Lactopress, Microfine. 
Formula : C12H22011 (340.30) Anhydrous  
C12H22011,.H20  (360.31) Monohydrate  
 
Funtional Category : Tablet & capsule Diluent.  
 
Description: lactose occurs as white to off-white crystalline particles or powder, 
odourless, slightly sweet tasting, a lactose in approximately 15% as sweet as 
sucrose, while a lactose is sweeter than the a lactose. 
 
 Typical Properties : LOD = 0.5%-1.0% 
 Water    = 4.5%-5.5% 
 Bulk Density  =  0.62 gm/cm3 
 Tapped Density  = 0.94/cm3 
 True Density   = 1.552 
 Melting point  = 201ºC-202ºC 
           Moisture Content=Approx. 5% w/w of water of crystallization & normally 
ranges between 4.5%-5-5%. 
 
 
 
 
 
 
Solubility 
Table-7 
Sr.No Solvents Solubility at 20ºC or Unless otherwise stated  
1 Chloroform Practically Insoluble  
2 Ethanol Practically Insoluble 
3 Ether Practically Insoluble 
4 Water 1 in 4.63 
1 in 3.14 at 40ºC 
1 in 2.04 at 50ºC 
1 in 1.68 at 60ºC 
1 in 1.07 at 80ºC 
 
Applications : It is widely used as filler or diluents in tablets, capsules & also in 
dry powder inhalations. 
 Various lactose grades are commercially available that have different 
particle size distribution and flow characteristics. Fine grades of lactose are used in 
preparation of tablets by wet granulations method, since of fine size permits better 
mixing with other formulation ingredients and utilized binder more efficiently 
  Spray dried lactose is directly compressible grade lactose which is more 
fluid and more compressible than crystalline form. Spray dried lactose is composed 
of pure a lactose monohydrate and small amount of amorphous lactose. 
 
 
5. AEROSIL 
 
Non proprietary name: 
 Colloidal silicon dioxide  
Functional category: 
 Pharmaceutical aid (suspending agent, tablet and capsule adjuvant) 
Synonyms: 
 Colloidal silica, fumed silica, light anhydrous silicic acid, silicic anhydride, 
silicon dioxide fumed, aerosol, cab-o-sil, syloid. 
Molecular weight: 
 60.08 
Characteristics: 
 Submicroscopic, light, loose, bluiswhite, odourless, tasteless,  non-gritty 
amorphous powder. 
Solubility : 
 Insoluble in purified water, forms a colloidal dispersion, soluble in hot 
solutions of alkali hydroxide, insoluble in acids, except hydrofluoric, insoluble in 
organic solvents.  
Stability and storage conditions: 
 Colloidal silicon dioxide is hygroscopic but absorbs large quantities of water 
without liquefying. Store in well closed container. 
Uses: 
• Drying agent for hygroscopic materials, absorbent dispensing agent 
for liquids in  powders or suppositories. 
• Glidants and antiadherents in tableting processes and encapsulation. 
• Thickening and suspending agent in gels.  
 
6. Magnesium Stearate  
Synonyms   Stearic acid magnesium salt, 
    Magnesium octadecanoate 
 
Chemical Name  Octadecanoic acid magnesium  
 
Nonproprientary Names 
    BP- Magnesium stearate 
    PhEur – Magneshi stearate 
    USPNF – Magnesium stearate 
 
Description  
 Magnesium stearate is a fine, white, precipitated, milled impalatable powder 
of low bulk density, having a faint, characteristic odor and taste. The powder is 
greasy to touch and readily adheres to skin. 
Applications 
 Magnesium stearate is widely used in cosmetics, foods, and 
pharmaceuticals. It is primarily used as lubricant in capsule and tablet 
manufacture at concentration between 0.25-50% concentrations.  
 
 
  
 
 
 
7. Material and Method 
 
PREFORMULATIONS STUDIES  
INDENTICATION AND CHARACTERIZATION OF ONDANSETRON 
HYDROCHLORIDE   
 
Infra-Red Absorption spectrum 
 The IR spectrum of Ondansetron Hydrochloride was determined and 
recorded using IR Spectro photometer. The KBr pellet method was used for 
preparation of ondansetron Hydro chloride. 
 
UV Spectrophotometer method 
 Weighed  accurately 100 mg pure ondansetron drug was taken and dissolved 
in 100ml of water. This made up to 100 mg/ ml solution. From this stock solution 
from 0.5ml  was taken and diluted with distilled water.The absorbance was 
measured at  310 nm using UV- spectrophotometer. 
 
Melting point 
 The melting point of ondanseton  was determined by capillary method.  
time over which sustained dose is released (Td) = 12 hrs
Desired constant release from sustained dose = Ko = D1Xkel
= (2) x (0.2235) = 0.447 mghr-1
= D1 = Ko/Ke1 = Ds/Ke1x T= (since Ko=Ds/T)
where Ds = sustained dosage
T= Time over which sustained dose is release.
Ds = D1 X Kel1  x T
2 x 0.2235 x 12- 4.364
Corrected initial dose = (Di)
2-(1.5 x 2x 0.2235)
= 2-0.6705
= 1.3295
Corrected initial dose Di = 1.3295
Total Dose = Di + Ds = 1.3295+ 4.364 = 5.69
5.69 mg= 5mg.
Dose Calculation 
initial Dose (Di) = 2mg
Biological half life of the drug (t1/2 ) = 3.1 hours
Elimination rate constat = 0.693/3.1 = 0.2235 hr-1
Time to reach peak plasma conc. (Tp) = 1.5 hrs 
 
 
 
 
 
 
 
7.1 LIST OF INSTRUMENTS 
 
Table-8 
 
Instruments used in the formulation and analysis of Ondansetron 
Sustained Release Tablets.  
 
 
Sr.NO 
 
NAME OF INSTRUMENTS 
 
MANUFACTURER 
 
APPLICATION  
 
 
1 
 
Tap Density Tester  
 
Electrolab 
 
Determine Bulk 
Density of Granules 
 
 
2 
 
Distal weighing balance  
 
Sartorius 
 
Used for weighing 
 
 
3 
 
Rotary machine 
 
Rimeck   
 
Used for compression of 
granulation  
 
 
4 
 
Hardness tester 
 
Pfizer  
 
Used for checking 
Hardness 
 
 
5 
 
Vernier  Caliper 
 
Mirotoyo corps 
 
For checking Thickness 
 
 
6 
 
Tray Drier 
 
Mixfill 
 
For Drying Granulation  
 
 
7 
 
Conventional Coating Machine 
 
KSD 
 
For Tablet Coating 
 
 
8 
 
UV spectrophotometer 
 
Mapada /Techcomp 
 
Assay of Drug 
 
 
  
The following materials were obtained from following commercial sources. 
 
Table-9 
 1) Ondansetron Hydrochlorided, Dihydrate  - Nactco Pharma Ltd, 
Hyderabad 
 
2) Lactose Monohydrate    - DMV International 
3) Microcrystalline Cellulose (pH 101)  - Signet  chemicals 
4) Pregelatinized starch    - Colorcon Asia Pvt. Ltd 
5) HPMC (K4M,K15M, K 100M)   - Coloron Asia Pvt. Ltd 
6) Magnesium Stearate    - Parag Fine Organics 
7) PEG 6000      - VaSudha Chemicals Pvt. Ltd 
8) Talc       -Nice chemical Pvt limited 
9) Dibutyl  Phathalate    - Merck Specialities Pvt. Ltd 
10)  Titanium Dioxide     - Kronos Internaitonal 
11) Isopropy1 Alcohol     - Lee Chang Yung chemical 
Pvt.Ltd 
The following materials were obtained from commercial sources and  
Used as received. 
 
 Ingredients used in the formulation development of Ondansetron 
Sustained Release Tablets- 
Table-10 
 Sr.No 
 
NAME OF INGREDIENTS 
 
SPECIFICATION 
 
NATURE 
 
APPLICATION 
 
 
1. 
 
Ondansetron Hydrochloride 
Equivalent Ondansetron 
 
 
USP 
 
Solid 
 
Active Drug 
 
2 
 
Lactose Monohydrate 
 
IP 
 
Solid 
 
Diluent 
 
 
3 
 
Microcrystalline celluslose 
 
IP 
 
Solid 
 
Diluent 
 
 
4 
 
Starch  
 
BP 
 
Solid 
 
Binder 
 
 
5 
 
Purified Water 
 
IH 
 
Liquid 
 
Vehicle 
 
 
6 
 
Microcrystalline Cellulose 
 
IP 
 
Solid 
 
Lubricant 
 
 
7 
 
Magnesium stearate 
 
IP 
 
Solid 
 
Lubricant 
 
 
 
 
Ingredients used in the Film Coating 
Table-11 
 
Sr.No 
 
NAME OF 
 
SPECIFICATION  
 
NATURE 
 
APPLICATION  
INGREDIENTS  
 
1. 
 
Hydroxypropylmethycell
ulose 
 
IP 
 
Solid 
 
Polymer 
 
 
2 
 
Dibutyl Phthalate 
 
IP 
 
 
Liquid 
 
Plasticizer 
 
 
3 
 
Polyethylene Glycol 
6000 
 
 
IP 
 
Solid 
 
Plasticizer 
 
4 
 
Talc  
 
IP 
 
Solid 
 
Glidant 
 
 
5 
 
Titanium Dioxide 
 
IP 
 
Solid 
 
Opacifier 
 
 
6 
 
Isopropyl Alcohol 
 
IP 
 
Liquid 
 
Vehicle 
 
 
7 
 
Dicholoromethane 
(Methylene 
Chloride) 
 
 
BP 
 
Liquid 
 
Vehicle  
 
 
 
 
Standard Curve for ondansetron hydrochloride 
 
   Procedure  
 100 mg of ondansetron hydrochloride was accurately weighed and then 
dissolved in 100 ml of water. This solution is having concentration 100 mg/ml. 
From this stock solution 5,10,15,20, 30,40,50 µg/ml by distilled water. Absorbance 
was measured at 310 nm using UV-spectrophotometer (MAPADA) .The standard 
plot  is plotted for absorbance verus concentration . 
 Table No 12 .  Standard Curve for ondansetron hydrochloride 
Sr.No Concentration in µg/ml Absorbance at 310 nm 
1 5 0.2096 
2 10 0.4352 
3 15 0.6148 
4 20 0.8412 
5 30 1.2110 
6 40 1.6431 
7 50 2.0150 
 
  R -  0.9997 
  A - 0.0224 
  B - 0.0400 
 
 
 
STANDARD CURVE  FOR  ONDANSETRON HCL 
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Table-13 
RATIO / CONCENTRATION OF POLYMER USED 
TO THE DRUG 
 
  
 
Sr. No 
 
 
Batch number 
 
Drug-polymer 
ratio 
 
1 
 
F-I (HPMC K 4 M) 
 
1:2 
 
 
2 
 
F-I (HPMC K 4 M) 
 
1:3 
 
 
3 
 
F-II (HPMC K 15 M) 
 
1:2 
 
 
4 
 
F-IV (HPMC K 15 M) 
 
1:3 
 
 
5 
 
F-V(HPMC K 100 LVP) 
 
1:2 
 
 
 
 
 
 
 
 
 
 
 
PREPARATION OF ONDANSETRON HYDROCHLORIDE  SR TABLETS. 
 
Granulation  
 Ondansetron Hydro chloride SR tablets was prepared by using wet 
granulation technique. Granulation is the process in which powder particles are 
made to adhere to form larger particles called granules. Granulation will commerce 
after mixing the necessary powdered ingredients, so that a uniform distribution of 
each ingredient through the mix is achieved. 
 
Reasons for granulation: 
•  To prevent segregation of constituents in the powder mixture. 
• To improve the flow properties of the mixture. 
• To improve the compression characteristics of the mixture. 
• Granules being denser than the parent powder mixture, occupy less volume 
per unit weight. They are therefore more convenient for storage. 
Procedure: 
1) Ondansetron Hydrochloride, lactose, avicel PH 101, first portion of HPMC 
K 100 LVP were passed through 40 mesh. 
2) Binding solution was prepared with water. It was added to step I and 
granulate them. 
3) Wet granules were passed through 12 mesh & dried for some times. 
4) Dried granules were through 20 mesh and prelubricated with rest of the 
portion of HPMC K 100 LVP . 
5) Prelubricated granules were lubricated with aerosol, talc which was 
already passed trough 40 mesh.6) Blend well for 30 minutes.7)Compress 
the blend  into tablet using tablet compression machine. 
Coating of the tablet: 
 Tablet coating is the application of coating composition to moving bed of 
tablets with concurrent use of heated air  to facilitate evaporation of solvent.  
Basis principles involve 
i) Insulation which influences the release pattern as little as possible   
      and  does not markedly changed the appearance. 
ii) Modified release with specific requirement and release mechanism adapted 
to body function in the digestive tract. 
iii) Colour coating which provides insulation or is combined with modified 
release coating.  
Procedure: 
 
1)  IPA was stirred in a colloidal mill and titanium dioxide was added 
slowly, avoiding powder floatation on the liquid surface. 
2) Methylene chloride was added and mixed well for thirty minutes to get 
uniform dispersion . 
3) Finally the above dispersion was passed through 200 mesh nylon cloth. 
4) The core tablets were coated in the coating pan.  
 
Preformulation studies 
 
Angle of repose 
 
 With care, dynamic angle of repose measurement can be replicated with 
relative standard deviation of approximately 2 % they are particularly  sensitive to 
change in particle size distribution and to moisture content and they provide rapid 
means of monitoring significant batch difference in these respells. 
 
θ  = tan-1 h/r 
Where, 
  θ - Angle of repose 
 H-Height of the pile 
 R-Radius of the base of the conical pile  
 
 Angle of repose was determined by using funnel method. Powder was paired 
from a funnel that can be raised vertically until a maximum cone heights, it was 
obtained. Diameter of heap, d was measured. 
 
The angle of respose calculated by above formula  
 
 
 
 
 
 
Table-14 
Angle of Respose as indicating of powder flow-properties 
 
Angle of repose (Degrees) Types or flow 
<20 Excellent 
20-30 Good 
30-34 Passable 
> 40 Very poor 
 
Bulk Density  
  Bulk density is of great importance when one considers the size of high dose 
capsule product (or) me homogeneity of how dose formulation in which where is 
large difference in drug and Excipients densities. Apparent bulk density is 
determined by pouring pre sieved (40 sieve) bulk drug into a graduated cylinder 
via a large and measuring the volume and weight “as it as”. 
 
Powder flow properties  
 
 One of the ways of measurement of free flowing ability of powder is 
compressibility. 
 Carr’s indes = (Vi – Vt) /Vi X 100 
 
      Vi = Tapped density 
      Vt = Initial bulk density   
Process  flow  chart  
 
    
Dispensing 
 
 
Preseiving and mixing 
 
 
Binder preparation 
 
 
Wet granulation 
 
 
Drying 
 
 
Prelubrication 
 
 
Lubrication 
 
Compression 
 
 
Coating 
     Table-15 
COMPOSITION  OF SUSTAINED RELEASE  TABLETS OF 
ONDANSETRON HYDROCHLORIDE 
I. FOR CORE TABLET
Batch
ingredients 
F-I F-II F-III F-IV F-V
(mg) ( mg) ( mg) ( mg) (mg)
Ondansetron HCl 5.02 5.02 5.02 5.02 5.02
Lactose Monohydrate 47.19 43.39 47.19 43.39 47.19
Microcrystalline 
Cellulose (Avicel PH 101)
18.3 16.83 18.3 16.83 18.3
Starch 7.5 7.5 7.5 7.5 7.5
Purified Water q.s q.s q.s q.s q.s
Magnesium stearate 0.5 0.5 0.5 0.5 0.5
HPMC K 4 M 10.04 15.06 - - -
HPMC K 15 M - - 10.04 15.06 -
HPMC K 100 LVP - - - - 10.04 
Aerosil 0.3 0.3 0.3 0.3 0.3
             
       
   Table-16     
II. Composition of coating suspension
Batch
ingredients 
(mg)
HPMC 15 cps 1.230
Dibutyl Phthalate 0.015
PEG 6000 0.055
Talc 0.55
Titanium Dioxide 0.200
Dichloromethane q.s
Isopropyl alcohol q.s
 
   
 
  Evaluation of tablets 
 Weight variation  
 Weight of 20 tablets was determined. From that average weight was 
calculated. Then individual tablet were weighed and the individual weight was 
compared with the average weight.  
 
Table-16 
Specification as BP 
 
S.No Average weight of the Tablets  Percentage deviation  
1 80 mg or less 10 
2 More than 80 mg but less than 250 mg 7.5 
3 250 mg or more 5 
 
Hardness 
 Although there is no official test for tablet hardness this property must be 
controlled during production to ensure that the product is firm enough to withstand  
handling without breaking, chipping etc., the hardness of a tablet is indicative of its 
tensile strength and is measured in term of pressure required to crush it when 
placed on its edge. Hardness of about 5 kg/cm2  is considered to be minimum for 
uncoated tablets for mechanical stability. The hardness had influence on 
disintegration and dissolution times. Hardness is the factor that affects the 
bioavailability. 
 
 
 
Friability 
 Friability generally refers to loss in weight of tablets in the container  due to 
chapping, abrasion, and erosion. The standard device available is “Friabilators” 
(Consist of circular plastic chamber, a divide into two compartments. The chamber 
rotates at a speed of 25 r.p.m and drops tablets by distance of 15 cm). the weight 
loss should not be more than one percent. 
 
Formula 
Percentage Friability = (initial weight – final weight / initial weight) X 100  
Procedure 
 10 tablets are weighed and transferred in to Friabilator. Then after 100 
revolutions per minute the tablets were unloaded and weight of the tablets was 
noted. The difference should not exceed one percent. 
Disintegration time 
 Tablet was added to 100 ml distilled water at 370c± 0.5 0C. Time required 
for complete dispersion of a tablet was measured win help of digital tablet 
disintegration test apparatus.  
 
Uniformity of content 
Procedure 
 Crush two tablets, taken the powder equivalent of dose 10mg, add 100 ml 
water. take 0.5ml and diluted with water.The measure the absorbance of resulting 
solution at 310 mm using UV- spectro photometrically.  
 
 
 
ACCELERATED STABILITY STUDIES 
 
Stability 
 Stability is officially defined as the time lapse during which the drug product 
retains the same properties and characteristics that it possessed at the time of 
manufacture. This process begins at early devolvement phases.  
 
 Instability in modern formulation is often detectable only after considerable 
storage period under normal condition. To assess the stability of a formulated 
product its usual to expose it to high stress conditions to enhance its detoriation 
and therefore the time required for testing is reduce common high stress like 
temperature and humidity. This will eliminate unsatisfactory formulation. 
 
Strategy of stability testing 
 
1. The study of drug decomposition kinetics 
2. The development of stability dosage form. 
3. Establishment of expiration date for commercially available drug product 
is some of the needs of stability testing.  
4. Data form stability studies should be provided on at least there primary 
batches of the drug product. 
5. The batches should be manufactured to a minimum of pilot scale. 
6. Important point of view of the safety of the patient, patient relieves a 
uniform dose of drug throughout the shelf life of the product. 
 
 
Table-18 
The Stability Storage Condition 
S.No Study Storage condition  Minimum period  
1. Long-term study 250 C±20C 
60 % ±5% RH 
12 month 
2 Intermediate study 300 C±20C 
65 % ±5% RH 
6 month 
3 Accelerated study 400 C±20C 
75 % ±5% RH 
6 month 
 
 
Procedure 
 Selected batches were placed in a high density polyethylene container, 
blister pack, strip pack etc. They are kept in stability chamber maintained at 400 C 
& 75 % RH. The stability studies were carried out for a period of one month. The 
tablets were tested and checked for the above mention specification. 
 
 
 
 
 
 
 
 
 
 
8. Results and Discussion 
Figure. No. 5 IR Spectrum of  ondansetron hydrochloride 
FTIR SPECTRUM
ACIC
St.Joseph's  College ( Autonomous )
Trichy-2
Spectrum Name: Sam=Ondansetronhcl.sp 
Date: 4/19/2008
Sam=Ondansetronhcl.pk
SAM_ON~1.SP  3601  4000.00  400.00  6.37  98.89  4.00  %T  3  2.00
REF 4000 98.89 2000 93.79 600
3408.66  6.37   3175.29  31.07  2922.21  46.79  2848.83  49.02  2775.96  48.30  
2719.76  45.57  2113.57  84.89  1840.05  89.29  1637.11  13.28  1530.33  63.15  
1456.04  30.11  1396.82  38.26  1277.54  61.91  1242.75  80.63  1202.17  70.33  
1127.26  59.56  1084.82  60.47  1042.84  76.57  922.49   52.55  847.50   82.91  
755.40   26.17  664.77   79.46  598.35   72.69  505.88   56.19  
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Table No. 17 
IR Spectrum of  ondansetron hydrochloride 
Sr. No Wave number Functional group
1. 1637.4 N = N stretching 
2. 755.40 CH bending aromatic   
3. 2848.83 
2719.76
Two distinct peaks methyl group 
4. 3408.06 NH stretching
5. 1840.5 C = o stretching 
Discussion 
IR spectrum was confirmed by ondansetron HCl
 
Table No. 17 
Active pharmaceutical Coonsideration  
Powder Properties of Formulation 
Sr. 
No
Formulation 
code
*Bulk 
Density(gm/ml)
*Angle of 
Repose 
Carr’s index 
%
1 F-I 0.333 21041’ 15.62
2 F-II 0.348 21043’ 11.90
3 F-III 0.375 21020’ 12.12
4 F-IV 0.352 24009’ 14.02
5 F-V 0.344 20010’ 15.62
 
*Average value of three observations.  
Discussion 
 The value of angle of respose and Carr’s index  less than 250  and 15 % 
respectively,  hence the flow properties all formulations complied within the limits.  
 
Dissolution Condition 
 
Apparatus     : USP Type – II (Paddle) 
Speed      : 75 rpm 
Time      : 1,4,8, and 12 
Dissolution medium   : 0.1 N HCL 
Qty. of Dissolution medium      :  900 ml 
Temperature     : 370C± 0.50C 
 
Preparation of 0.1 NHCL 
 Weight and transfer accurately about 55.37 mg of Ondasetron HCl (44.4mg 
of  Tizanidine) working standard into a 100 ml volumetric flash, add 70ml of 
methanol, sonicate for 5-10 and and make a volume with methano. (conce 444.44 
mcg /ml) 
  
 From this solution take 5 ml into 50 ml volumetric flask volume make up by 
using dissolution medium (conc, 44.044 mgc/ml) 
 
 From this solution take 5 ml into 50ml volumetric flask volume make by 
using 0.1N HCL.(conc.4.44 mcg/ml) 
  
 From this solution take 5 ml into 10ml volumetric flask volume make by 
using mobile phase. (conc. 2.22 mcg/ml) 
 
Chromatographic conditions 
 
Column : Lichroshere, CN, 250x 4.6mm, 5 micrometer 
Wavelength : 247 nm 
Flow rate  : 1.0ml /min 
Injection volume : 50 Microlitres 
Runtime : 15 min 
Table No. 18 
System suitability 
 
Parameter Limit results 
Theratica plate NLT 850 4542.92 
Assmetry NMT 2 0. 9 
Capacity factor NLT 2 2.5. 
 
 
 
 
 
 
 
 
 
 
Table No. 19 
PHYSICAL PARAMETERS OF FABRICATED TABLETS 
(n=20) 
Sr.No Formulations 
 
Average 
Tablet 
Weight 
(mg) 
Hardness
(Kg/cm) 
Thickness
(mm) 
 
Diameter 
(mm) 
Friability 
(%) 
 
1 
 
F-I 
 
91.13 
 
4.9 
 
2.53 
 
5.92 
 
0.54 
 
2 
 
F-II 
 
91.12 
 
4.9 
 
2.52 
 
5.92 
 
0.53 
 
3 
 
F-III 
 
91.32 
 
4.9 
 
 
2.52 
 
5.92 
 
0.56 
 
4 
 
F-IV 
 
90.57 
 
4.9 
 
2.52 
 
5.92 
 
0.52 
 
5 
 
F-V 
 
91.35 
 
5.0 
 
2.53 
 
5.92 
 
0.50 
 
 
 
 
 
 
 
 
 
Table No. 20 
CUMULATIVE PERCENT RELEASED OF ONDANSETRON 
HYDROCHLORIDE FROM FABRICATED SR MATRIX TABLETS F-I 
TO F-V IN pH 6.8 PHOSPHATE BUFFER
Time in Hours F-I F-II F-III F-IV F-V
1 29.5 25.9 28.6 28.4 20.4
4 72.8 68.4 85.6 70.7 36.3
8 102.2 101.4 85.6 98.4 72.4
12 104.4 103.4 99.4 100.8 100.21
 
                                       Table No. 21 
ASSAY OF FABRICATED FORMULATION
Sr. No Formulation % of 
ondansetron
1 F-I 99.73
2 F-II 99.85
3 F-III 98.26
4 F-IV 98.92
5 F-V 100.23
 
 
 
 
 
  
 
 
 
Table No. 22 
 IN VITRO RELEASE PROFILE OF F-V TABLET KEPT AFTER 
STORAGE AT 400C & 75% RH, ROOM TEMPERATURE 
 FOR 30 DAYS. 
 
Batch Number 
Percentage drug release 
F-V 
 
Time 
Interval (hrs) 
Initial After 30 Days 
1 20.4 20.8 
4 50.1 50.7 
8 72.4 72.6 
12 100.21 100.23 
Assay (%) 100.23 100.15 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure. No. 6 ONDANSETRON INVITRO RELEASE CURVE OF 
FORMULATION F-1 
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Figure. No. 7 ONDANSETRON INVITRO RELEASE CURVE OF 
FORMULATION F-2 
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Figure. No. 9 ONDANSETRON INVITRO RELEASE CURVE OF 
FORMULATION F-3 
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Figure. No. 10 ONDANSETRON INVITRO RELEASE CURVE OF 
FORMULATION F-4 
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Figure. No. 11 ONDANSETRON INVITRO RELEASE CURVE OF 
FORMULATION F-5 
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Figure. No. 12 ONDANSETRON INVITRO RELEASE CURVE OF 
FORMULATION F-5  STABILITY BATCH 
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Figure. No. 13 COMPARATIVE IN VITRO DRUG RELEASE FOR 
F1, F2 , F3, F4, F5  
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9. Summary and Conclusion 
 
¾ The present work is to develop a formulation with ondansetron  
         Hydro chloride as a sustained Release tablet dosage from for the  
         treatment of cancer Chemotherapy in nausea and vomiting. 
¾ Under, this, drug  characterization and drug excipients interaction studies 
were carried out. The drug characterization showed satisfactory results. 
¾ The physico chemical properties of the finished Poduct is complies with 
specifications.  
¾ Ondansetron Hydrochloride SR tablets are formulated by using HPMC 
polymers in different concentrations.  
¾ Five different formulations are formulated and evaluated. 
¾ Only formulation five is better sustained release than compare with  other 
formulation. 
¾ Formulation five gives a release of 100.23 for an 12 hours.  
¾ The prepared formulations are stable at or below 400C, hence it can be easily 
stored at room tempetature. 
¾ This work concluding that has achieved the objectives of sustained release 
up to 12 hours.  
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